Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission.

IF 3.9 Q2 ONCOLOGY
Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2021-09-22 eCollection Date: 2021-01-01 DOI:10.2147/BLCTT.S330008
Karan Seegobin, Muhamad Alhaj Moustafa, Liuyan Jiang, Han W Tun
{"title":"Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission.","authors":"Karan Seegobin,&nbsp;Muhamad Alhaj Moustafa,&nbsp;Liuyan Jiang,&nbsp;Han W Tun","doi":"10.2147/BLCTT.S330008","DOIUrl":null,"url":null,"abstract":"<p><p>Richter transformation (RT) is defined as the transformation of chronic lymphocytic leukemia (CLL) to a high-grade B cell lymphoma. It usually carries a dismal prognosis and represents an unmet need for novel therapeutic interventions. We report a case of an 80-year-old male who developed double-hit (DH) RT with translocations of MYC and BCL6 after 5 years of watchful waiting for standard-risk CLL. He was treated with induction therapy consisting of 4 cycles of anthracycline-based chemoimmunotherapy (CIT) and 2 cycles of platinum-based CIT with intrathecal methotrexate for CNS prophylaxis followed by continuous maintenance therapy with ibrutinib. He achieved complete remission after the induction therapy. At the time of writing, four and a half years after the diagnosis with DH-RT, he remains in complete remission without evidence of RT or CLL. The novel therapeutic approach used in successful treatment of this patient should be further explored.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"11 ","pages":"67-72"},"PeriodicalIF":3.9000,"publicationDate":"2021-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/c7/blctt-11-67.PMC8474063.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood and Lymphatic Cancer-Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/BLCTT.S330008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Richter transformation (RT) is defined as the transformation of chronic lymphocytic leukemia (CLL) to a high-grade B cell lymphoma. It usually carries a dismal prognosis and represents an unmet need for novel therapeutic interventions. We report a case of an 80-year-old male who developed double-hit (DH) RT with translocations of MYC and BCL6 after 5 years of watchful waiting for standard-risk CLL. He was treated with induction therapy consisting of 4 cycles of anthracycline-based chemoimmunotherapy (CIT) and 2 cycles of platinum-based CIT with intrathecal methotrexate for CNS prophylaxis followed by continuous maintenance therapy with ibrutinib. He achieved complete remission after the induction therapy. At the time of writing, four and a half years after the diagnosis with DH-RT, he remains in complete remission without evidence of RT or CLL. The novel therapeutic approach used in successful treatment of this patient should be further explored.

Abstract Image

Abstract Image

Abstract Image

成功的非移植治疗双重打击Richter转化和长期缓解。
Richter转化(RT)被定义为慢性淋巴细胞白血病(CLL)向高级别B细胞淋巴瘤的转化。它通常预后不佳,对新型治疗干预的需求尚未得到满足。我们报告一例80岁男性患者,在观察等待标准风险CLL 5年后出现MYC和BCL6易位的双重命中(DH) RT。患者接受诱导治疗,包括4个周期的蒽环类化学免疫治疗(CIT)和2个周期的铂类化学免疫治疗加鞘内甲氨蝶呤用于中枢神经系统预防,然后持续使用依鲁替尼维持治疗。诱导治疗后,患者病情完全缓解。在撰写本文时,在诊断为DH-RT四年半后,他仍然处于完全缓解状态,没有RT或CLL的证据。新的治疗方法用于成功治疗该患者应进一步探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
7.10%
发文量
16
审稿时长
16 weeks
期刊介绍: Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信